Assignee
ALMIRALL SA
ES·41 granted patents·29 pending applications·179 citations·filing 2005–2025
Top patents by PatentIndex Score
70 records- 0196US7750023B2Quinuclidine derivatives and medicinal compositions containing the sameALMIRALL SA·Filed 2008·Granted Jul 6, 2010·27 cites·13 claims
- 0295US7897617B2Quinuclidine derivatives and medicinal compositions containing the sameALMIRALL SA·Filed 2010·Granted Mar 1, 2011·21 cites·13 claims
- 0394US9333195B2Quinuclidine derivatives and medicinal compositions containing the sameALMIRALL SA·Filed 2015·Granted May 10, 2016·8 cites·14 claims
- 0494US8802699B2Quinuclidine derivatives and medicinal compositions containing the sameALMIRALL SA·Filed 2013·Granted Aug 12, 2014·12 cites·10 claims
- 0593US9056100B2Quinuclidine derivatives and medicinal compositions containing the sameALMIRALL SA·Filed 2014·Granted Jun 16, 2015·9 cites·14 claims
- 0691US9687478B2Quinuclidine derivatives and medicinal compositions containing the sameALMIRALL SA·Filed 2016·Granted Jun 27, 2017·5 cites·14 claims
- 0789US7964615B2Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the β2 adrenergic receptorALMIRALL SA·Filed 2006·Granted Jun 21, 2011·15 cites·24 claims
- 0889US7776879B2Quinuclidine carbamate derivatives and their use as M3 antagonistsALMIRALL SA·Filed 2007·Granted Aug 17, 2010·12 cites·29 claims
- 0987USRE46417EQuinuclidine derivatives and their use as muscarinic M3 receptor ligandsALMIRALL SA·Filed 2016·Granted May 30, 2017·4 cites·30 claims
- 1087US9233108B2Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activitiesALMIRALL SA·Filed 2012·Granted Jan 12, 2016·9 cites·3 claims
- 1186US10034867B2Quinuclidine derivatives and medicinal compositions containing the sameALMIRALL SA·Filed 2017·Granted Jul 31, 2018·2 cites·21 claims
- 1284US7893087B2Quinuclidine derivatives and medicinal compositions containing the sameALMIRALL SA·Filed 2006·Granted Feb 22, 2011·5 cites·22 claims
- 1382US9562039B2Salts of 2-amino-1-hydroxyethyl-8-hydroxyquinolin-2(1H)-one derivatives having both β2 adrenergic receptor agonist and M3 muscarinic receptor antagonist activitiesALMIRALL SA·Filed 2014·Granted Feb 7, 2017·10 cites·11 claims
- 1481US7879874B2Quinuclidine derivatives and medicinal compositions containing the sameALMIRALL SA·Filed 2006·Granted Feb 1, 2011·3 cites·23 claims
- 1579US9757383B2Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activitiesALMIRALL SA·Filed 2015·Granted Sep 12, 2017·2 cites·7 claims
- 1679US9549934B2Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activitiesALMIRALL SA·Filed 2015·Granted Jan 24, 2017·2 cites·3 claims
- 1778US9254262B2Dosage and formulationALMIRALL SA·Filed 2012·Granted Feb 9, 2016·6 cites·23 claims
- 1875US10759793B22-(pyrazolopyridin-3-yl)pyrimidine derivatives as JAK inhibitorsALMIRALL SA·Filed 2016·Granted Sep 1, 2020·3 cites·13 claims
- 1975US10005771B2Bicyclic derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activitiesALMIRALL SA·Filed 2015·Granted Jun 26, 2018·2 cites·26 claims
- 2074US9643961B2Cyclohexylamine derivatives having β2 adrenergic antagonist and M3 muscarinic antagonist activitiesALMIRALL SA·Filed 2016·Granted May 9, 2017·2 cites·3 claims
- 2173US10588895B2Quinuclidine derivatives and medicinal compositions containing the sameALMIRALL SA·Filed 2018·Granted Mar 17, 2020·0 cites·13 claims
- 2273US9579316B2Salts of 2-amino-1-hydroxyethyl-8-hydroxyquinolin-2(1H)-one derivatives having both muscarinic receptor antagonist and β2 adrenergic receptor agonist activitiesALMIRALL SA·Filed 2014·Granted Feb 28, 2017·3 cites·9 claims
- 2370US9737520B2Aclidinium for use in improving the quality of sleep in respiratory patientsALMIRALL SA·Filed 2016·Granted Aug 22, 2017·4 cites·15 claims
- 2467US10085974B2Dosage and formulationALMIRALL SA·Filed 2012·Granted Oct 2, 2018·1 cites·22 claims
- 2567US9518050B2Cyclohexyl and quinuclidinyl carbamate derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activityALMIRALL SA·Filed 2013·Granted Dec 13, 2016·2 cites·46 claims
- 2665US9907807B2Topical pharmaceutical compositionsALMIRALL SA·Filed 2015·Granted Mar 6, 2018·2 cites·6 claims
- 2765US8820321B2Storage system for powdered pharmaceuticals, and inhaler equipped with this systemALMIRALL SA·Filed 2012·Granted Sep 2, 2014·2 cites·4 claims
- 2865US2025381172A1Novel dosage and formulationALMIRALL SA·Filed 2025·Application pending·0 cites
- 2965US2021330628A1Pharmaceutical Compositions Comprising Dimethyl FumarateALMIRALL SA·Filed 2021·Application pending·0 cites
- 3065US2016310457A1Pharmaceutical compositions comprising dimethyl fumarateALMIRALL SA·Filed 2014·Application pending·0 cites
- 3160US10300072B2Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activitiesALMIRALL SA·Filed 2017·Granted May 28, 2019·0 cites·24 claims
- 3260US8375940B2Storage system for powdered pharmaceuticals and inhaler equipped with this systemALMIRALL SA·Filed 2007·Granted Feb 19, 2013·1 cites·10 claims
- 3359US11000517B2Dosage and formulationALMIRALL SA·Filed 2018·Granted May 11, 2021·0 cites·29 claims
- 3459US10434268B2Inhalation device for powdered drugsALMIRALL SA·Filed 2013·Granted Oct 8, 2019·2 cites·9 claims
- 3557US9388189B2Pyrrolotriazinone derivatives as PI3K inhibitorsALMIRALL SA·Filed 2013·Granted Jul 12, 2016·1 cites·20 claims
- 3657US8051851B2Inhaler for the administration of powdered pharmaceuticals, and a powder cartridge system for use with this inhalerALMIRALL SA·Filed 2005·Granted Nov 8, 2011·2 cites·17 claims
- 3756US2023374158A1Bispecific molecules and methods of treatment using the sameALMIRALL SA·Filed 2021·Application pending·0 cites
- 3854US2023235040A1Anti-il-36 antibodies and methods of use thereofALMIRALL SA·Filed 2021·Application pending·0 cites
- 3953US2014343097A15-(2-1-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one for the treatment of lung functionALMIRALL SA·Filed 2014·Application pending·0 cites
- 4052US2014038928A15-(2--1-hydroxyethyl-8-hydroxyquinolin-2 (1h)-one and its use in the treatment of pulmonary diseasesALMIRALL SA·Filed 2013·Application pending·0 cites
- 4151US2015140099A1Novel dosage form and formulation of abediterolALMIRALL SA·Filed 2013·Application pending·0 cites
- 4246US2016303108A1Novel dosage form and formulation of abediterolALMIRALL SA·Filed 2016·Application pending·0 cites
- 4346US2014005178A1Azabiphenylaminobenzoic acid derivatives as dhodh inhibitorsALMIRALL SA·Filed 2013·Application pending·0 cites
- 4446US2020255478A1Novel compounds activating the nrf2 pathwayALMIRALL SA·Filed 2018·Application pending·0 cites
- 4545US7954492B2Pharmaceutical powder cartridge, and inhaler equipped with sameALMIRALL SA·Filed 2005·Granted Jun 7, 2011·0 cites·15 claims
- 4644US2014000602A1Inhalation device for drugs in powder formALMIRALL SA·Filed 2013·Application pending·0 cites
- 4744US2016331733A1New use of aclidiniumALMIRALL SA·Filed 2016·Application pending·0 cites
- 4844US2021220368A1Compositions comprising timolol and their use in the treatment of rosacea by topical administrationALMIRALL SA·Filed 2017·Application pending·0 cites
- 4943US2017158699A1Addition salts of (s)-2-(1-(6-amino-5-cyanopyrimidin-4-ylamino)ethyl)-4-oxo-3-phenyl-3,4-dihydropyrrolo[1,2-f][1,2,4]triazine-5-carbonitrileALMIRALL SA·Filed 2015·Application pending·0 cites
- 5042US2015328194A1New use of aclidiniumALMIRALL SA·Filed 2013·Application pending·0 cites
Showing the top 50 of 70 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →